Cerebral Vein Thrombosis and Direct Oral Anticoagulants: A Review.

Autor: Umurungi J; Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy., Ferrando F; Department of Medical Sciences, University of Turin, 10126 Turin, Italy., Cilloni D; Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy., Sivera P; Haematology and Cellular Therapies Unit, A.O. Ordine Mauriziano di Torino, 10128 Turin, Italy.
Jazyk: angličtina
Zdroj: Journal of clinical medicine [J Clin Med] 2024 Aug 12; Vol. 13 (16). Date of Electronic Publication: 2024 Aug 12.
DOI: 10.3390/jcm13164730
Abstrakt: Cerebral venous thrombosis (CVT) is a rare type of cerebrovascular event in which the thrombosis occurs in a vein of the cerebral venous system. The diagnosis could be challenging due to the great clinical variability, but the outcome is favourable in most cases, especially in the case of early diagnosis. Anticoagulant therapy is the core of CVT management and currently consists of heparin in the acute phase followed by vitamin K antagonists (VKAs) in the long term. The ideal duration of anticoagulant therapy is still unclear, and the same criteria for the treatment of extracerebral venous thromboembolism currently apply. In this paper, we reviewed the literature regarding the use of direct oral anticoagulants (DOACs) in CVT since in recent years a considerable number of studies have been published on the use of these drugs in this specific setting. DOACs have already been shown to be equally effective with VKAs in the treatment of venous thromboembolism. In addition to efficacy, DOACs appear to have the same safety profile, being, on the other hand, more manageable, as they do not require close monitoring with continuous personalised dose adjustments. In addition, a further advantage of DOACs over VKAs is the possibility of anticoagulant prophylaxis using a reduced dosage of the drug. In conclusion, although the use of DOACs appears from preliminary studies to be effective and safe in the treatment of CVT, additional studies are needed to include these drugs in the treatment of CVT.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje